Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII.
Benoit SC, Sheldon RJ, Air EL, Messerschmidt P, Wilmer KA, Hodge KM, Jones MB, Eckstein DM, McOsker CC, Woods SC, Seeley RJ.
Int J Obes Relat Metab Disord. 2003 May;27(5):550-6.PMID: 12704398 [PubMed - indexed for MEDLINE]Related articles